CEDAR KNOLLS, N.J.,
Aug. 2, 2018 /PRNewswire/
-- MYOS RENS Technology Inc. ("MYOS" or "the Company")
(NASDAQ: MYOS), a biotherapeutics and bionutrition company and
the owner of Fortetropin®, a proprietary bioactive composition
derived from fertilized egg yolk that helps build lean muscle,
announced today that it will announce financial results for the
second quarter and first half of 2018 on Wednesday, August 8 after the market closes.
The company will host a conference call on Thursday, August 9, 2018 at 11:00 am ET, at which time MYOS Chief Executive
Officer Joseph Mannello will provide
commentary on earnings results for the second quarter and first
half ended June 30, 2018 and provide
updates on its four ongoing clinical studies.
The Company will announce earnings results for the first quarter
ended March 31, 2018, prior to the
conference call.
Conference Call Details:
Call
Date/Time:
|
Thursday, August 9,
2018 at 11:00 am ET
|
Call Title:
|
MYOS RENS Technology
Second Quarter 2018 Financial Results Conference Call
|
Dial In:
|
877-407-4019 from the
U.S.; international callers may telephone 201-689-8337,
approximately 10 minutes before the call.
|
A digital replay will be available by telephone approximately
two hours after the completion of the call until November 9, 2018 and may be accessed by dialing
877-660-6853 from the U.S. or 201-612-7415 for international
callers, using the Conference ID# 13682085.
This call will be simultaneously webcast. The webcast will be
available on the MYOS website, www.myosrens.com, in the "Investor
Relations" section. The webcast will be archived and available at
the same web address for two weeks following the call.
About MYOS RENS Technology Inc.
MYOS RENS Technology Inc. (MYOS), "The Muscle Company™", is a
Cedar Knolls, NJ-based
bionutrition company that develops and markets products that
improve muscle health and performance. MYOS is the owner of
Fortetropin®, a fertilized egg yolk-based product manufactured via
a proprietary process to retain and optimize its biological
activity. Fortetropin® has been clinically shown to increase muscle
size and lean body mass in conjunction with resistance training.
MYOS believes Fortetropin® has the potential to redefine existing
standards of physical health and wellness. For more information,
please visit www.MYOSRENS.com.
Forward-Looking Statements
Any statements in this release that are not historical facts
are forward-looking statements. Actual results may differ
materially from those projected or implied in any forward-looking
statements. Such statements involve risks and uncertainties,
including but not limited to those relating to product and customer
demand, market acceptance of our products, the ability to create
new products through research and development, the successful
results of strategic initiatives, the successful launch of our
products, including Qurr® products, the success
of our research and development, including the clinical studies
described above, the results of the clinical evaluation of
Fortetropin® and its effects, the ability to
enter into new partnership opportunities and the success of our
existing partnerships, the ability to generate the forecasted
revenue stream and cash flow from sales of our products, the
ability to continue increasing our revenue and gross profit
margins, the ability to achieve a sustainable, profitable business,
the effect of economic conditions, the ability to protect our
intellectual property rights, competition from other providers and
products, the continued listing of our securities on the Nasdaq
Stock Market, risks in product development, our ability to raise
capital to fund continuing operations, and other factors discussed
from time to time in our filings with the Securities and
Exchange Commission. We undertake no obligation to update or revise
any forward-looking statement for events or circumstances after
the date on which such statement is made except as required by
law.
These statements have not been evaluated by the Food and Drug
Administration. Our products are not intended to diagnose, treat,
cure or prevent any disease.
Investor Relations:
Porter LeVay & Rose
Michael Porter, President
Phone: 212-564-4700
Email: MYOS@plrinvest.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/myos-rens-technology-announces-the-date-for-the-release-of-second-quarter-and-first-half-2018-results-conference-call-and-webcast-300690583.html
SOURCE MYOS RENS Technology